Johnson & Johnson (JNJ) Sees FY13 Revs at $70.4B - $71.1B; Est. at $71.1B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Maintains Sell on Johnson & Johnson (JNJ); Drug Business Spin Still Unlikely
April 17, 2013 10:49 AM EDTGoldman Sachs maintained a Sell rating on Johnson & Johnson (NYSE: JNJ) with a price target of $80.00. Analyst Jami Rubin reiterated his view that Johnson & Johnson should consider a break up, though he does not think management will consider this option.
... More
Johnson & Johnson (JNJ) Tops Q1 EPS by 3c; Reaffirms FY EPS Outlook
April 16, 2013 7:47 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q1 EPS of $1.44, $0.03 better than the analyst estimate of $1.41. Revenue for the quarter came in at $17.5 billion versus the consensus estimate of $17.46 billion.
Johnson & Johnson still sees FY 2013 EPS $5.35-$5.45, versus the consensus of $5.40.
... More
